abstract |
The invention relates to substituted 1,2-ethylenediamines of general formula (I), wherein the groups R1 - R13, A, B, L and i are as defined in the description and in the claims. The invention also relates to the use thereof for treating Alzheimer's disease (AD) and similar diseases. |